نوع مقاله : مقاله مروری
نویسنده
دانشیار، عضو هیئت علمی دانشکده علوم توانبخشی دانشگاه شهید بهشتی تهران، ایران
چکیده
کلیدواژهها
موضوعات
عنوان مقاله [English]
نویسنده [English]
Background and Aim: Glaucoma is one of the most common chronic eye diseases that can potentially result in bilateral blindness, and may also be related to psychological disturbances. The purpose of the present study was evaluation of the relationship between glaucoma and psychiatric disorders.
Materials and Methods: In the current article,we reviewed the available articles on psychiatry disorders in patients with glaucoma based on specialized databases and identified articles based on their abstracts and full-texts.
Results: Evaluation of available articles revealed that patients with glaucoma often have coexisting psychiatric disorders such as anxiety and depression. The prevalence of anxiety and depression in glaucoma patients in different countries is approximately between 13-33% and 10-57%m respectively. Also, the association between Alzheimer's disease and chronic glaucoma is heterogeneous. It should be noted that the differences in results may be attributed to study design sand sample sizes. In connection with personality traits in glaucoma patients, immature defense style, perfectionistic pattern, neuroticism, hypochondriacal tendencies, irritability, and type A behavioral pattern are reported, as well.
Conclusion: According to the results,in chronic diseases such as glaucoma, psychological factors are closely related to medical guidelines. These factors include memory deficit, depression, anxiety, personality type, and side effects of the drugs. Increased use of immature defense mechanisms, and accompanying depression and anxiety have been associated with decreased quality of life in these patients. The existence of type A behavioral pattern with high neuroticism can provide vulnerability to glaucoma.
کلیدواژهها [English]
10. Musch, D.C. ,Niziol, L.M ,Janz, N.K ,Gillespie, B.W. Trends in and Predictors of Depression Among Participants in the Collaborative Initial Glaucoma Treatment Study. American Journal of OphthalmologyVolume 197, January 2019, Pages 128-135. ##
11. Zhang, D ,Fan, Z. Gao, X , Huang, W. ,Yang, Q. Illness uncertainty, anxiety and depression in Chinese patients with glaucoma or cataract. Scientific ReportsOpen Access 2018,8(1):11671 Article number DOI:10.1038/s41598-018-29489-1##
12. Tastan S, Iyigun E, Bayer A, et al. Anxiety, depression and quality of life in Turkish patients with glaucoma. Psychol Rep. 2010;106:343–357. ##
13. Zhou C, Qian S, Wu P, et al. Anxiety and depression in Chinese patients with glaucoma: sociodemographic, clinical and self-reported correlates. J Psychosom Res. 2013;75:75–82. ##
14. Fasih U, Hamirani MM, Jafri AR, et al. Assessment of anxiety and depression in primary open angle glaucoma patients (a study of 100 cases). Pak J Ophthalmol. 2010;26:143–147. ##
15. Wang SY, Singh K, Lin SC. Prevalence and predictors of depression among participants with glaucoma in a nationally representative population sample. Am J Ophthalmol. 2012;154:436–444. ##
16. Skalicky S, Goldberg I. Depression and quality of life in patients with glaucoma: a cross-sectional analysis using the Geriatric Depression Scale-15, assessment of function related to vision, and the Glaucoma Quality of Life-15. J Glaucoma. 2008;17:546–551. ##
17. Ramulu PY, West SK, Munoz B, et al. Driving cessation and driving limitation in glaucoma: the Salisbury Eye Evaluation Project. Ophthalmology. 2009;116:1846–1853. ##
18. Ramulu PY, Swenor BK, Jefferys JL, et al. Difficulty with outloud and silent reading in glaucoma. Invest Ophthalmol Vis Sci. 2013;54:666–672. ##
19. Tosini G, Baba K, Hwang CK, Iuvone PM . Melatonin: An underappreciated player in retinal physiology and pathophysiology. Exp Eye Res. 2012; 103:82–89. ##
20. Tastan S, Iyigun E, Bayer A, Acikel C . Anxiety, depression, and quality of life in Turkish patients with glaucoma. Psychol Rep.2010; 106:343–357. ##
21. Jayawant SS, Bhosle MJ, Anderson RT, Balkrishnan R .Depressive symptomatology, medication persistence, and associated healthcare costs in older adults with glaucoma. J Glaucoma.2007; 16:513–520. ##
22. Ghiso JA, Doudevski I, Ritch R, Rostagno AA . Alzheimer's disease and
glaucoma: Mechanistic similarities and differences. J Glaucoma.2013; 22(Suppl 5):S36–S38. ##
23. Chen WW, Wang N, Cai S, Fang Z, Yu M, Wu Q, Tang L, Guo B, Feng Y, Jonas JB, Chen X, Liu X, Gong Q. Structural brain abnormalities in patients with primary open-angle glaucoma: A study with 3 T MR imaging. Invest Ophthalmol Vis Sci.2013; 54:545–554. ##
24. Yu L, Xie B, Yin X, Liang M, Evans AC, Wang J, Dai C. Reduced cortical thickness in primary open-angle glaucoma and its relationship to the retinal nerve fiber layer thickness. PLoS One.2013; 8:e73208. ##
25. Qing G, Zhang S, Wang B, Wang N. Functional MRI signal changes in primary visual cortex corresponding to the central normal visual field of patients with primary open-angle glaucoma. Invest Ophthalmol Vis Sci.2010; 51:4627–4634. ##
26. Kirby E, Bandelow S, Hogervorst E . Visual impairment in Alzheimer's disease: A critical review. J Alzheimers Dis.2010; 21:15–34. ##
27. Sadun AA, Bassi CJ. Optic nerve damage in Alzheimer's disease. Ophthalmology.1990; 97:9–17. ##
28. Wostyn P, Audenaert K, De Deyn PP. Alzheimer's disease: Cerebral glaucoma? Med Hypotheses.2010; 74:973–7. ##
29. Tamura H, Kawakami H, Kanamoto T, Kato T, Yokoyama T, Sasaki K, Izumi Y, Matsumoto M, Mishima HK. High frequency of open-angle glaucoma in
Japanese patients with Alzheimer's disease. J Neurol Sci.2006; 246:79–83. ##
30. Bayer AU, Ferrari F, Erb C . High occurrence rate of glaucoma among patients with Alzheimer's disease. Eur Neurol. 2002a; 47:165–168. ##
31. Bayer AU, Keller ON, Ferrari F, Maag KP. Association of glaucoma with neurodegenerative diseases with apoptotic cell death: Alzheimer's disease and Parkinson's disease. Am J Ophthalmol. 2002b; 133:135–137. ##
32. Kessing LV, Lopez AG, Andersen PK, Kessing SV. No increased risk of developing Alzheimer disease in patients with glaucoma. J Glaucoma.2007; 16:47–51. ##
33. McKinnon SJ. Glaucoma: Ocular Alzheimer's disease? Front Biosci. 2003; 8:s1140–s1156. ##
34. Kim TW, Pettingell WH, Jung YK, Kovacs DM, Tanzi RE. Alternative cleavage of Alzheimer-associated presenilins during apoptosis by a caspase-3 family protease. Science.1997; 277:373–376. ##
35. Inoue T, Kawaji T, Tanihara H. Elevated levels of multiple biomarkers of Alzheimer's disease in the aqueous humor of eyes with open-angle glaucoma. Invest Ophthalmol Vis Sci. 2013; 54:5353–5358. ##
36. Wostyn P, Audenaert K, De Deyn PP. Alzheimer's disease and glaucoma: Is there a causal relationship? Br J Ophthalmol. 2009; 93:1557–1559. ##
37. Yin H, Chen L, Chen X, Liu X. Soluble amyloid beta oligomers may contribute to apoptosis of retinal ganglion cells in glaucoma. Med Hypotheses.2008;71:77–80. ##
38. Cronin-Golomb A, Corkin S, Rizzo JF, Cohen J, Growdon JH, Banks KS .Visual dysfunction in Alzheimer's disease: Relation to normal aging. Ann Neurol.1991; 29:41–52. ##
39. Chapman FM, Dickinson J, McKeith I, Ballard C. Association among visual hallucinations, visual acuity, and specific eye pathologies in Alzheimer's disease:Treatment implications. Am J Psychiatry.1999; 156:1983–1985. ##
40. DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: Meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med. 2000; 160:2101–2107. ##
41. Lim MC, Shiba DR, Clark IJ, Kim DY, Styles DE, Brandt JD, Watnik MR,
Barthelow IJ . Personality type of the glaucoma patient. J Glaucoma. 2007;16:649–654. ##
42. Bubella RM, Bubella DM, Cillino S. Type a behavior pattern: is it a risk factor for open-angle chronic glaucoma? J Glaucoma. 2014;23(4):199–201. ##
43. Pappa C, Hyphantis T, Pappa S, Aspiotis M, Stefaniotou M, Kitsos G, Psilas K, Mavreas V. Psychiatric manifestations and personality traits associated with compliance with glaucoma treatment. J Psychosom Res. 2006; 61:609–617. ##
44. Çakmak H, Altinyazar V, Yilmaz SG, Ömürlü İK, Kocatürk T, Yazici ,et al.A, The temperament and character personality profile of the glaucoma patient. BMC Ophthalmol. 2015 Oct 1;15:125. doi: 10.1186/s12886-015-0117-9##
45. Evans JR, Fletcher AE, Wormald RP. Depression and anxiety in visually impaired older people. Ophthalmology.2007; 114:283–288. ##
46. AndrewCamp,Sarah R.Wellik,Jonathan H.Tzu,WilliamFeuer, Kristopher L.Arheart, AnanthSastry, AnatGalor. Dry eye specific quality of life in veterans using glaucoma drops. Contact Lens and Anterior Eye., Volume 38, Issue 3, June 2015, Pages 220-225. ##
47. Ritch R, Krupin T, Henry C, Kurata F (1994) Oral imipramine and acute angle closure glaucoma. Arch Ophthalmol. 112:67–68. ##
48. Costagliola C, Parmeggiani F, Sebastiani A. SSRIs and intraocular pressure modifications: Evidence, therapeutic implications and possible mechanisms.CNS Drugs. 2004; 18:475–484. ##
49. Fraunfelder FW, Fraunfelder FT, Keates EU . Topiramate-associated acute, bilateral, secondary angle-closure glaucoma. Ophthalmology.2004; 111:109–111. ##
50. Roughead EE, Kalisch LM, Pratt NL, Killer G, Barnard A, Gilbert AL. Managing glaucoma in those with co-morbidity: Not as easy as it seems. Ophthalmic Epidemiol. 2012; 19:74–82. ##
51. Robin AL (1997) The role of alpha-agonists in glaucoma therapy. Curr Opin Ophthalmol. 1997; 8:42–49. ##
52. Kurtz S, Ashkenazi I, Melamed S. Major depressive episode secondary toantiglaucoma drugs. Am J Psychiatry.1993; 150:524–525. ##
53. Rowe TO. Acetazolamide delirium. Am J Psychiatry.1977 ;134:587–588. ##
54. Schweitzer I, Maguire K, Tuckwell V. Antiglaucoma medication and clinical depression. Aust N Z J Psychiatry. 2001;35:569–571. ##
55. Kaiserman I, Kaiserman N, Elhayany A, Vinker S. Topical beta-blockers are not associated with an increased risk of treatment for depression. Ophthalmology.2006; 113:1077–1080. ##
56. Zimmerman TJ, Kooner KS, Kandarakis AS, Ziegler LP. Improving the
therapeutic index of topically applied ocular drugs. Arch Ophthalmol.1984; 102:551–553. ##
)